MARKET

BFRIW

BFRIW

Biofrontera
NASDAQ
0.0304
+0.0082
+36.93%
Closed 14:47 05/20 EDT
OPEN
0.0304
PREV CLOSE
0.0222
HIGH
0.0304
LOW
0.0304
VOLUME
750
TURNOVER
0
52 WEEK HIGH
0.2770
52 WEEK LOW
0.0221
MARKET CAP
--
P/E (TTM)
-0.0293
1D
5D
1M
3M
1Y
5Y
1D
This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Benzinga · 1d ago
This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday
Benzinga · 1d ago
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Biofrontera Price Target Maintained With a $3.00/Share by Benchmark
Dow Jones · 1d ago
Biofrontera Cut to Speculative Buy From Buy by Benchmark
Dow Jones · 1d ago
Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3
Benzinga · 1d ago
BIOFRONTERA INC <BFRI.O>: BENCHMARK CUTS TO SPECULATIVE BUY FROM BUY
Reuters · 1d ago
Biofrontera downgraded to Speculative Buy from Buy at Benchmark
TipRanks · 1d ago
More
About BFRIW
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Webull offers Biofrontera Inc stock information, including NASDAQ: BFRIW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRIW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BFRIW stock methods without spending real money on the virtual paper trading platform.